The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2025 | Managing patients with large B-cell lymphoma who progress following CAR-T
In this video, Andrea Kuhnl, MD, King’s College Hospital, London, United Kingdom, briefly comments on the management of patients with large B-cell lymphoma (LBCL) who progress or relapse after CAR T-cell therapy, highlighting the effectiveness of bispecific antibodies in this patient population. Dr Kuhnl notes that bispecifics are highly efficacious, with long-term remission rates observed in pivotal studies. Although real-world data shows slightly inferior outcomes compared to these studies, prior CAR-T administration does not seem to significantly impact the outcomes of patients treated with bispecifics. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting, held in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Most patients who progress or relapse after CAR-T would be considered for CD20xCD3 bispecific antibody therapies. These are highly effective treatments. We’ve seen long-term remission rates from long-term follow-up from the pivotal studies. In some patients, these treatments are actually considered alternative to CAR-T. We’ve now seen more and more real-world data coming through looking at bispecific outcomes including those who receive bispecifics post CAR-T and it looks like overall outcomes are slightly inferior to what we’ve seen in the pivotal studies, which was expected given the high-risk patient population in the real-world setting, but there doesn’t seem to be a significant impact on whether or not patients had prior CAR-T...
Most patients who progress or relapse after CAR-T would be considered for CD20xCD3 bispecific antibody therapies. These are highly effective treatments. We’ve seen long-term remission rates from long-term follow-up from the pivotal studies. In some patients, these treatments are actually considered alternative to CAR-T. We’ve now seen more and more real-world data coming through looking at bispecific outcomes including those who receive bispecifics post CAR-T and it looks like overall outcomes are slightly inferior to what we’ve seen in the pivotal studies, which was expected given the high-risk patient population in the real-world setting, but there doesn’t seem to be a significant impact on whether or not patients had prior CAR-T. But those who relapse very soon after CAR-T, those patients have poor outcomes but we really don’t know whether they would do any better with alternative treatments, I suspect they would. But these ultra high-risk patients, would do very poorly with whichever post-CAR-T treatment you would consider.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consultancy: Kite Gilead, Roche, Abbvie, BMS; Honoraria: Kite Gilead, Astra Zeneca.
